EA201690014A1 - Популяции клеток, способы трансдифференцировки и способы их применения - Google Patents

Популяции клеток, способы трансдифференцировки и способы их применения

Info

Publication number
EA201690014A1
EA201690014A1 EA201690014A EA201690014A EA201690014A1 EA 201690014 A1 EA201690014 A1 EA 201690014A1 EA 201690014 A EA201690014 A EA 201690014A EA 201690014 A EA201690014 A EA 201690014A EA 201690014 A1 EA201690014 A1 EA 201690014A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pancreatic
transdifferential
application
cell populations
Prior art date
Application number
EA201690014A
Other languages
English (en)
Other versions
EA035413B1 (ru
Inventor
Сара Фербер
Original Assignee
Ордженисис Лтд.
Тел Хашомер-Медикал Рисерч, Инфрастракче Энд Сервисиз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ордженисис Лтд., Тел Хашомер-Медикал Рисерч, Инфрастракче Энд Сервисиз Лтд. filed Critical Ордженисис Лтд.
Publication of EA201690014A1 publication Critical patent/EA201690014A1/ru
Publication of EA035413B1 publication Critical patent/EA035413B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

В настоящем изобретении предложены способы последовательного и регулируемого по времени введения панкреатических факторов транскрипции для индукции непанкреатических клеток с целью трансдифференцировки и созревания по панкреатической β-клеточной линии. В настоящем изобретении также предложены способы идентификации, выделения и обогащения клеток, предрасположенных к трансдифференцировке, а также способы лечения дегенеративного панкреатического нарушения, такого как диабет.
EA201690014A 2013-06-13 2014-06-13 Популяции клеток, способы трансдифференцировки и способы их применения EA035413B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834759P 2013-06-13 2013-06-13
US201361834767P 2013-06-13 2013-06-13
PCT/IB2014/002164 WO2014207578A2 (en) 2013-06-13 2014-06-13 Cell populations, methods of transdifferention and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201690014A1 true EA201690014A1 (ru) 2016-06-30
EA035413B1 EA035413B1 (ru) 2020-06-10

Family

ID=52142772

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690014A EA035413B1 (ru) 2013-06-13 2014-06-13 Популяции клеток, способы трансдифференцировки и способы их применения

Country Status (13)

Country Link
US (2) US9982236B2 (ru)
EP (1) EP3007710B1 (ru)
JP (1) JP6650393B2 (ru)
KR (1) KR102181336B1 (ru)
CN (1) CN105555950B (ru)
AU (1) AU2014300650B2 (ru)
BR (1) BR112015031253B1 (ru)
CA (1) CA2915143C (ru)
EA (1) EA035413B1 (ru)
IL (1) IL243030B (ru)
MX (1) MX2015017235A (ru)
SG (1) SG11201510209SA (ru)
WO (1) WO2014207578A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207578A2 (en) 2013-06-13 2014-12-31 Orgenesis Ltd. Cell populations, methods of transdifferention and methods of use thereof
JP6749239B2 (ja) 2013-09-24 2020-09-02 ガイナー ライフ サイエンシズ，インク． 細胞インプラントのガス処理用システム
MA41296A (fr) * 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
CN105002142B (zh) * 2015-07-09 2019-04-05 深圳市人民医院 直接重编程小鼠肝细胞为胰岛β细胞的方法及应用
CN110167613B (zh) 2016-11-15 2022-01-11 吉纳生命科学公司 适合用于皮下植入物的经皮气体扩散装置
CA3062412A1 (en) 2017-05-04 2018-11-08 Giner Life Sciences, Inc. Robust, implantable gas delivery device and methods, systems and devices including same
WO2018207179A1 (en) * 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
CN113663054A (zh) * 2021-08-30 2021-11-19 丁小明 Isl1在制备抑制移植胰岛早期铁死亡的药物中的用途和细胞

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4837316A (en) 1985-08-29 1989-06-06 Fujirebio Kabushiki Kaisha Alkylamide derivatives with H2 -receptor antagonistic and cytoprotective action
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427940A (en) 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE69435026D1 (de) 1993-08-16 2007-10-31 Res Dev Foundation Ein homeobox-faktor der insulin-expression in pankreatischen inselnzellen stimuliert
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
ATE321880T1 (de) 1995-11-30 2006-04-15 Res Dev Foundation Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
JP2000513227A (ja) 1996-06-24 2000-10-10 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド インスリン分泌細胞の単離および増殖方法
US6114113A (en) 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
CA2221195A1 (en) 1997-11-14 1999-05-14 Chantal E. Holy Biodegradable polymer matrix
US6143293A (en) 1998-03-26 2000-11-07 Carnegie Mellon Assembled scaffolds for three dimensional cell culturing and tissue generation
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US7524492B2 (en) 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
CA2463914A1 (en) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
US7722894B2 (en) 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
IL162131A0 (en) 2001-12-07 2005-11-20 Geron Corp Islet cells from human embryonic stem cells
AU2003217658A1 (en) 2002-02-22 2003-09-09 University Of Florida Cellular trans-differentiation
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
US20060122104A1 (en) 2002-05-28 2006-06-08 Presnell Sharon C Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
ES2440654T3 (es) 2003-05-05 2014-01-29 Ben-Gurion University Of The Negev Research And Development Authority Preparaciones poliméricas reticuladas inyectables y usos de las mismas
JP2006525994A (ja) 2003-05-12 2006-11-16 サラ ファーバー， 非膵島組織における調節された膵ホルモンの産生を誘導する方法
US20060205072A1 (en) 2003-08-27 2006-09-14 Nobuko Uchida Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CA2548464C (en) 2003-12-09 2013-02-12 Ben-Gurion University Of The Negev Research And Development Authority Pulse-medium perfusion bioreactor with improved mass transport for multiple 3-d cell constructs
EP1778296B1 (en) 2004-07-20 2012-06-06 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
US20090239298A1 (en) 2004-08-25 2009-09-24 Technion Research & Development Foundation Ltd. Methods of generating embryoid bodies using three dimensional scaffolds
US8679484B2 (en) 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
EP1856246B1 (en) 2005-03-07 2015-07-15 Technion Research & Development Foundation Limited Natural tissue-derived decellularized matrix and methods of generating and using same
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
CN101553245A (zh) 2006-07-19 2009-10-07 佛罗里达大学研究基金会有限公司 用于细胞重编程的组合物及其用途
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
AU2007335753B2 (en) 2006-12-18 2013-12-05 Ben Gurion University Of The Negev Scaffolding for tissue regeneration or repair
US20100226976A1 (en) 2007-07-11 2010-09-09 Marcelle Machluf Encapsulated mesenchymal stem cells and uses thereof
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2009126927A2 (en) 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Methods of generating insulin-producing cells
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
WO2011016423A1 (ja) * 2009-08-02 2011-02-10 学校法人 東京女子医科大学 膵島細胞シート、製造方法及びその利用方法
JP2011223993A (ja) 2010-03-30 2011-11-10 Kumamoto Univ 幹細胞の分化誘導方法
EP2580320B1 (en) * 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
US9731046B2 (en) 2012-02-21 2017-08-15 Ben Gurion University Of The Negev Research And Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
WO2014102801A1 (en) 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
PL2994528T3 (pl) 2013-05-08 2024-04-22 Prokidney Organoidy zawierające wyizolowane komórki nerkowe oraz ich zastosowania
WO2014207578A2 (en) 2013-06-13 2014-12-31 Orgenesis Ltd. Cell populations, methods of transdifferention and methods of use thereof
WO2015125147A1 (en) 2014-02-20 2015-08-27 B. G. Negev Technologies And Applications Ltd Anionic polyplexes for use in the delivery of nucleic acids
WO2015184313A1 (en) 2014-05-30 2015-12-03 Secant Medical, Inc. Water-mediated preparations of polymeric materials
WO2015186127A1 (en) 2014-06-02 2015-12-10 B. G. Negev Technologies And Applications Ltd Site-selective modification of polysaccharides and applications thereof
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3400074B1 (en) 2016-01-07 2021-10-20 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Compositions for generating immunotolerant responses
WO2017175229A1 (en) 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Polysaccharide compositions and uses thereof
US20170290954A1 (en) 2016-04-07 2017-10-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for treating spinal cord injury
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof

Also Published As

Publication number Publication date
CN105555950B (zh) 2021-03-05
US10947509B2 (en) 2021-03-16
BR112015031253B1 (pt) 2021-09-28
BR112015031253A2 (pt) 2017-08-22
US9982236B2 (en) 2018-05-29
EP3007710B1 (en) 2021-07-28
WO2014207578A2 (en) 2014-12-31
CA2915143C (en) 2021-08-03
KR20160034896A (ko) 2016-03-30
CA2915143A1 (en) 2014-12-31
MX2015017235A (es) 2017-05-04
SG11201510209SA (en) 2016-01-28
AU2014300650B2 (en) 2019-11-21
KR102181336B1 (ko) 2020-11-24
AU2014300650A1 (en) 2016-01-21
US20180340146A1 (en) 2018-11-29
US20160130559A1 (en) 2016-05-12
EA035413B1 (ru) 2020-06-10
EP3007710A4 (en) 2017-03-22
CN105555950A (zh) 2016-05-04
IL243030B (en) 2021-05-31
JP6650393B2 (ja) 2020-02-19
EP3007710A2 (en) 2016-04-20
JP2016521559A (ja) 2016-07-25
WO2014207578A3 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EA201690014A1 (ru) Популяции клеток, способы трансдифференцировки и способы их применения
PH12018500452A1 (en) Novel modulators and methods of use
MX2021004007A (es) Moduladores de linfocitos t reguladores multivalentes.
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
EA202193044A2 (ru) Способы лечения таупатии
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MY178142A (en) Anti-phf-tau antibodies and their uses
MX2016006356A (es) Metodos de tratamiento de una tauopatia.
EA201591527A1 (ru) Новые производные пиридина
IN2014DN08481A (ru)
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
MY197129A (en) Electrochemical coupling of two phenols which differ in their oxidation potential
NZ738538A (en) 6-amino-quinoline-3-carbonitrils as cot modulators
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2015012341A (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.
EA201690763A1 (ru) Лечение рака поджелудочной железы
MA39387A1 (fr) Colorants réactifs fluorescents, procédé de production et utilisation de ceux-ci
EA201992431A1 (ru) Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
EA201501174A1 (ru) Фармацевтический препарат для применения в эндорадионуклидной терапии
MX2016003248A (es) Metodos de uso de anticuerpos anti-lgr5.
EA201500055A1 (ru) Способ добычи нефти и соответствующая система